title: [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
abstract: Radium-223 dichloride (Xofigo®, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment.
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland. r.tauber@tum.de.
authors.forename: R
authors.initials: R
authors.lastname: Tauber
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland.
authors.forename: J
authors.initials: J
authors.lastname: Gschwend
authors.affiliation: Institut für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Scheidhauer
authors.affiliation: Institut für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Eiber
authors.affiliation: Institut für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Krönke
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary*; D004307:Dose-Response Relationship, Radiation; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging*; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D011883:Radium / Q000627:therapeutic use*; D063189:Symptom Assessment; D016896:Treatment Outcome
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals; C581106:radium Ra 223 dichloride; D011883:Radium
keywords: Alpha ray therapy; Bone metastases; Castration-resistant prostate cancer; Next generation hormonal treatment; Radionuclide therapy; Thrombocytopenia